Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Accure Therapeutics Publishes Pivotal Preclinical Efficacy Study in Epilepsy
Details : The study results show that the ACT-03, when administered in animal models over one week, can slow the progression of the disease by reducing the severity and number of spontaneous seizures (up to seven weeks after initial drug administration).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2021
Details : ACT-01 is a peptidomimetic first-in-class disease-modifying treatment for multiple sclerosis (MS) and acute optic neuritis, the latter with orphan drug designation by the US FDA and the EMA in the EU.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2021
Lead Product(s) : Privosegtor,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Simbec Research
Deal Size : Inapplicable
Deal Type : Inapplicable
BN201 SAD MAD Study in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 15, 2018
Lead Product(s) : Privosegtor,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Simbec Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
